
Earl D Silverman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7104981/publications.pdf Version: 2024-02-01



FADE D SILVEDMAN

#	Article	IF	CITATIONS
1	Outcome of Antibodyâ€Mediated Fetal Heart Disease With Standardized Antiâ€Inflammatory Transplacental Treatment. Journal of the American Heart Association, 2022, 11, e023000.	1.6	15
2	Looking Back and Marching Forward: New Features in 2022. Journal of Rheumatology, 2022, 49, 237-238.	1.0	0
3	Characterization of recurrent thrombosis in pediatric antiphospholipid syndrome. American Journal of Hematology, 2022, 97, .	2.0	2
4	Treatment of Childhood-onset Proliferative Lupus Nephritis in the 21st Century: A Call to Catch Up With the Evidence. Journal of Rheumatology, 2022, , jrheum.220196.	1.0	0
5	Predicting Macrophage Activation Syndrome in Childhood-onset Systemic Lupus Erythematosus Patients at Diagnosis. Journal of Rheumatology, 2021, 48, 1450-1457.	1.0	10
6	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. Journal of Rheumatology, 2021, 48, 852-858.	1.0	19
7	Efficacy and Safety of Tocilizumab for Polyarticularâ€Course Juvenile Idiopathic Arthritis in the Openâ€Label Twoâ€Year Extension of a Phase III Trial. Arthritis and Rheumatology, 2021, 73, 530-541.	2.9	16
8	Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multiethnic Cohort. Journal of Rheumatology, 2021, 48, 1417-1421.	1.0	5
9	Evaluation of self-report screening measures in the detection of depressive and anxiety disorders among children and adolescents with systemic lupus erythematosus. Lupus, 2021, 30, 1327-1337.	0.8	1
10	Effects of Transplacental Dexamethasone Therapy on Fetal Immune-Mediated Complete Heart Block. Fetal Diagnosis and Therapy, 2021, 48, 183-188.	0.6	8
11	Worse Quality of Life, Function, and Pain in Children With Enthesitis, Irrespective of Their Juvenile Arthritis Category. Arthritis Care and Research, 2020, 72, 441-446.	1.5	15
12	Realâ€World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort. Arthritis Care and Research, 2020, 72, 897-906.	1.5	14
13	Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. Rheumatology, 2020, 59, 90-98.	0.9	40
14	Earlier use of systemic immunosuppression is associated with fewer ophthalmic surgeries in paediatric non-infectious uveitis. British Journal of Ophthalmology, 2020, 104, 938-942.	2.1	11
15	Cutaneous sequelae in neonatal lupus: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 83, 440-446.	0.6	17
16	Timing of Childhoodâ€onset Systemic Lupus Erythematosus Diagnosis Relative to Menarche Impacts Final Height. Arthritis Care and Research, 2020, , .	1.5	4
17	Coughing up clues: 16-year-old girl with acute haemoptysis. BMJ Case Reports, 2020, 13, e233251.	0.2	0
18	Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease. Arthritis Research and Therapy, 2019, 21, 223.	1.6	13

#	Article	IF	CITATIONS
19	A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. Rheumatology, 2019, 58, 1393-1399.	0.9	15
20	Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus. Journal of Rheumatology, 2019, 46, 731-738.	1.0	18
21	FRI0533â€ETHNICITY AND NEONATAL LUPUSRISK IN A LARGE MULTI-ETHNIC COHORT. , 2019, , .		Ο
22	60â€Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset with SLE. , 2019, , .		3
23	Evaluation of Dry Eye Disease in Children With Systemic Lupus Erythematosus and Healthy Controls. Cornea, 2019, 38, 581-586.	0.9	13
24	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis and Rheumatology, 2019, 71, 411-419.	2.9	45
25	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2019, 46, 166-175.	1.0	12
26	A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus. Human Molecular Genetics, 2018, 27, 2392-2404.	1.4	34
27	Features, Treatment, and Outcomes of Macrophage Activation Syndrome in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2018, 70, 616-624.	2.9	61
28	Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. Pediatric Rheumatology, 2018, 16, 17.	0.9	8
29	Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Annals of the Rheumatic Diseases, 2018, 77, 21-29.	0.5	96
30	From Childhood to Adulthood: Disease Activity Trajectories in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 750-757.	1.5	18
31	Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genetics in Medicine, 2018, 20, 435-443.	1.1	404
32	CS-36â \in Recommendations for the assessment of systemic lupus erythematosus in canada. , 2018, , .		0
33	GG-11â€Identifying genetic variants for monogenic lupus and macrophage activation syndrome (MAS) in childhood onset systemic lupus erythematosus (SLE). , 2018, , .		Ο
34	Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Annals of the Rheumatic Diseases, 2018, 77, 1742-1749.	0.5	40
35	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 1426-1439.	1.0	43
36	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. Molecular Medicine, 2018, 24, 24.	1.9	12

#	Article	IF	CITATIONS
37	Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. Arthritis Care and Research, 2017, 69, 124-132.	1.5	16
38	From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenileâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 1627-1635.	1.5	42
39	Serial echocardiography for immuneâ€mediated heart disease in the fetus: results of a riskâ€based prospective surveillance strategy. Prenatal Diagnosis, 2017, 37, 375-382.	1.1	34
40	Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Juvenileâ€Onset Proliferative Lupus Nephritis. Arthritis Care and Research, 2017, 69, 1887-1894.	1.5	9
41	Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients. Pediatric Rheumatology, 2017, 15, 18.	0.9	16
42	Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis. Arthritis Research and Therapy, 2017, 19, 41.	1.6	34
43	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	5.8	314
44	Genomics of Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2017, 43, 415-434.	0.8	36
45	Malignancy in Pediatric-onset Systemic Lupus Erythematosus. Journal of Rheumatology, 2017, 44, 1484-1486.	1.0	14
46	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatric Rheumatology, 2017, 15, 68.	0.9	39
47	Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids. Pediatric Rheumatology, 2016, 14, 58.	0.9	15
48	Impact of Disease Duration on Vascular Surrogates of Early Atherosclerosis in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2016, 68, 237-246.	2.9	16
49	Ghost busting—taking the sheet off the ghost. Rheumatology International, 2016, 36, 455-456.	1.5	1
50	Ghost busting—taking the sheet off the ghost. Clinical Rheumatology, 2016, 35, 841-842.	1.0	0
51	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2016, 75, 1092-1098.	0.5	72
52	Brief Report: Endothelial Progenitor Cell Phenotype and Function Are Impaired in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2257-2262.	2.9	36
53	Childhood-onset systemic lupus erythematosus. Current Opinion in Rheumatology, 2015, 27, 483-492.	2.0	18
54	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	3.3	139

#	Article	IF	CITATIONS
55	Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset Systemic Lupus Erythematosus. Journal of Rheumatology, 2015, 42, 2304-2309.	1.0	19
56	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2015, 74, 1854-1860.	0.5	192
57	Immunosuppressive Therapies for the Maintenance Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis. Journal of Rheumatology, 2015, 42, 1392-1400.	1.0	29
58	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726.	9.4	310
59	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases, 2015, 74, 1110-1117.	0.5	251
60	Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. Journal of Rheumatology, 2015, 42, 2419-2426.	1.0	34
61	Presentation and outcome of paediatric membranous non-proliferative lupus nephritis. Pediatric Nephrology, 2015, 30, 113-121.	0.9	18
62	Association of Healthâ€Related Quality of Life in Childhoodâ€Onset Systemic Lupus Erythematosus With Ethnicity: Results From a Multiethnic Multicenter Canadian Cohort. Arthritis Care and Research, 2014, 66, 1767-1774.	1.5	21
63	A149: Does Prenatal Exposure to Antimalarial Decrease the Risk of Neonatal Lupus: a Bayesian Perspective. Arthritis and Rheumatology, 2014, 66, S193-S193.	2.9	4
64	A170: Neoplasms in Pediatric Patients with Rheumatic Diseases Exposed to Biologics-A Quarternary Centre's Experience. Arthritis and Rheumatology, 2014, 66, S220-S221.	2.9	7
65	Aplastic anemia associated with systemic lupus erythematosus in children – case report and review of the literature. Clinical Case Reports (discontinued), 2014, 2, 319-322.	0.2	1
66	A26: Longitudinal Disease Trajectory of Juvenile Dermatomyositis. Arthritis and Rheumatology, 2014, 66, S41-S41.	2.9	2
67	A18: Risk Factors for Symptomatic Avascular Necrosis in Childhood-Onset Systemic Lupus Erythematous. Arthritis and Rheumatology, 2014, 66, S29-S29.	2.9	1
68	A42: Antiâ€Ro and Anti‣a Antibodies in the General Pregnant Population: Rates and Fetal Outcomes. Arthritis and Rheumatology, 2014, 66, S63.	2.9	3
69	The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 3463-3475.	2.9	69
70	A153: Longâ€ŧerm Outcomes of Childhoodâ€Onset Systemic Lupus Erythematosus in Adulthood. Arthritis and Rheumatology, 2014, 66, S198.	2.9	1
71	A15: Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis. Arthritis and Rheumatology, 2014, 66, S25-S25.	2.9	3
72	Ten Common Mistakes in the Management of Lupus Nephritis. American Journal of Kidney Diseases, 2014, 63, 667-676.	2.1	34

#	Article	IF	CITATIONS
73	Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Annals of the Rheumatic Diseases, 2014, 73, 557-566.	0.5	65
74	Systematic Review of the Quality of Prognosis Studies in Systemic Lupus Erythematosus. Arthritis Care and Research, 2014, 66, 1536-1541.	1.5	8
75	A19: Rituximab Therapy has a Rapid and Durable Response for Refractory Cytopenia in Childhood-Onset Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2014, 66, S30-S30.	2.9	5
76	Chicken or the Egg: Anorexia Nervosa and Systemic Lupus Erythematosus in Children and Adolescents. Pediatrics, 2014, 133, e447-e450.	1.0	15
77	Immunosuppressive Therapies for the Induction Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis. Journal of Rheumatology, 2014, 41, 1998-2007.	1.0	35
78	Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis?. Pediatric Rheumatology, 2013, 11, 11.	0.9	40
79	Cardiovascular risk in pediatric-onset rheumatological diseases. Arthritis Research and Therapy, 2013, 15, 212.	1.6	53
80	Influence of ethnicity on childhoodâ€onset systemic lupus erythematosus: Results from a multiethnic multicenter Canadian cohort. Arthritis Care and Research, 2013, 65, 152-160.	1.5	52
81	Increased statistical power with combined independent randomization tests used with multiple-baseline design. Journal of Clinical Epidemiology, 2013, 66, 691-694.	2.4	5
82	Cytomegalovirus infection in childhood-onset systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2013, 8, 137-146.	0.3	24
83	Psychiatric Illness of Systemic Lupus Erythematosus in Childhood: Spectrum of Clinically Important Manifestations. Journal of Rheumatology, 2013, 40, 506-512.	1.0	38
84	Longterm Outcomes and Damage Accrual in Patients with Childhood Systemic Lupus Erythematosus with Psychosis and Severe Cognitive Dysfunction. Journal of Rheumatology, 2013, 40, 513-519.	1.0	31
85	Effect of autoimmune diseases on cognitive function. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 112, 1275-1283.	1.0	7
86	In Memoriam – Duncan A. Gordon, 1930–2012. Journal of Rheumatology, 2013, 40, 209-213.	1.0	0
87	An update on childhood-onset systemic lupus erythematosus. Current Opinion in Rheumatology, 2013, 25, 616-622.	2.0	43
88	Association of Smoking With Cutaneous Manifestations in Systemic Lupus Erythematosus. Arthritis Care and Research, 2013, 65, 1275-1280.	1.5	60
89	Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. Annals of the Rheumatic Diseases, 2013, 72, 1503-1509.	0.5	12
90	Congenital Heart Block Maternal Sera Autoantibodies Target an Extracellular Epitope on the α1G T-Type Calcium Channel in Human Fetal Hearts. PLoS ONE, 2013, 8, e72668.	1.1	28

#	Article	IF	CITATIONS
91	Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient group?. Clinical and Experimental Rheumatology, 2013, 31, 645-52.	0.4	4
92	Reversible Splenial Lesion Syndrome in Pediatric Systemic Lupus Erythematosus: Figure 1 Journal of Rheumatology, 2012, 39, 1698-1699.	1.0	10
93	Predicting longitudinal trajectory of bone mineral density in paediatric systemic lupus erythematosus patients. Annals of the Rheumatic Diseases, 2012, 71, 1686-1691.	0.5	16
94	Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E59-67.	3.3	151
95	Neuropsychiatric Lupus: The Prevalence and Autoantibody Associations Depend on the Definition: Results from the 1000 Faces of Lupus Cohort. Seminars in Arthritis and Rheumatism, 2012, 42, 179-185.	1.6	124
96	Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care and Research, 2012, 64, 375-383.	1.5	164
97	The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nature Reviews Nephrology, 2011, 7, 718-729.	4.1	207
98	Use of Intravenous Gamma Globulin and Corticosteroids in the Treatment of Maternal Autoantibody-Mediated Cardiomyopathy. Journal of the American College of Cardiology, 2011, 57, 715-723.	1.2	104
99	Prolongation of the Atrioventricular Conduction in Fetuses Exposed to Maternal Anti-Ro/SSA and Anti-La/SSB Antibodies Did Not Predict Progressive Heart Block. Journal of the American College of Cardiology, 2011, 57, 1487-1492.	1.2	96
100	Low bone mineral density is present in newly diagnosed paediatric systemic lupus erythematosus patients. Annals of the Rheumatic Diseases, 2011, 70, 1991-1994.	0.5	16
101	Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?. Autoimmunity Reviews, 2010, 9, 756-760.	2.5	46
102	Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care and Research, 2010, 62, 527-536.	1.5	86
103	Non-Cardiac Manifestations of Neonatal Lupus Erythematosus. Scandinavian Journal of Immunology, 2010, 72, 223-225.	1.3	89
104	Clinical and Serologic Factors Associated with Lupus Pleuritis. Journal of Rheumatology, 2010, 37, 747-753.	1.0	28
105	Rheumatic Disease and Carotid Intima-Media Thickness. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1014-1026.	1.1	166
106	Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Annals of the Rheumatic Diseases, 2010, 69, 718-722.	0.5	129
107	The Importance of the Level of Maternal Anti-Ro/SSA Antibodies as a Prognostic Marker of the Development of Cardiac Neonatal Lupus Erythematosus. Journal of the American College of Cardiology, 2010, 55, 2778-2784.	1.2	231
108	Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nature Reviews Rheumatology, 2010, 6, 538-546.	3.5	254

#	Article	IF	CITATIONS
109	Barriers to Healthcare in a Multiethnic Cohort of Systemic Lupus Erythematosus (SLE) Patients: Patient and Physician Perceptions. Clinical Medicine: Arthritis and Musculoskeletal Disorders, 2009, 2, CMAMD.S2136.	0.0	0
110	The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multiethnic Cohort. Journal of Rheumatology, 2009, 36, 1200-1208.	1.0	111
111	Identification of <i>IRAK1</i> as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6256-6261.	3.3	218
112	Autoantibodies in Pediatric Systemic Lupus Erythematosus: Ethnic Grouping, Cluster Analysis, and Clinical Correlations. Journal of Rheumatology, 2009, 36, 416-421.	1.0	64
113	Initial Validation of a Novel Protein Biomarker Panel for Active Pediatric Lupus Nephritis. Pediatric Research, 2009, 65, 530-536.	1.1	108
114	Comparison of Patients with Juvenile Psoriatic Arthritis and Nonpsoriatic Juvenile Idiopathic Arthritis: How Different Are They?. Journal of Rheumatology, 2009, 36, 2033-2041.	1.0	36
115	Ethnic Differences in Pediatric Systemic Lupus Erythematosus. Journal of Rheumatology, 2009, 36, 2539-2546.	1.0	136
116	Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intimaâ€media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis and Rheumatism, 2009, 60, 1496-1507.	6.7	125
117	Neutrophil gelatinase–associated lipocalin is a predictor of the course of global and renal childhoodâ€onset systemic lupus erythematosus disease activity. Arthritis and Rheumatism, 2009, 60, 2772-2781.	6.7	121
118	B-Cell Depletion for Autoimmune Thrombocytopenia and Autoimmune Hemolytic Anemia in Pediatric Systemic Lupus Erythematosus. Pediatrics, 2009, 123, e159-e163.	1.0	61
119	Pediatric Systemic Lupus Erythematosus. , 2009, , 161-167.		1
120	Difference in disease features between childhoodâ€onset and adultâ€onset systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 58, 556-562.	6.7	447
121	A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 59, 206-213.	6.7	100
122	Clinical and Laboratory Characteristics and Long-Term Outcome of Pediatric Systemic Lupus Erythematosus: A Longitudinal Study. Journal of Pediatrics, 2008, 152, 550-556.	0.9	286
123	Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry. Pediatrics, 2008, 122, e1100-e1107.	1.0	193
124	Sinus Bradycardia After Intravenous Pulse Methylprednisolone. Pediatrics, 2007, 119, e778-e782.	1.0	63
125	Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 631-638.	6.7	36
126	Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 1966-1973.	6.7	76

#	Article	IF	CITATIONS
127	Identification of novel susceptibility genes in childhoodâ€onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis and Rheumatism, 2007, 56, 4164-4173.	6.7	71
128	Chest CT findings in pediatric Wegener's granulomatosis. Pediatric Radiology, 2007, 37, 57-62.	1.1	31
129	Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. Journal of Rheumatology, 2007, 34, 2112-9.	1.0	25
130	Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. Journal of Pediatrics, 2006, 148, 683-686.	0.9	100
131	Leflunomide in juvenile idiopathic arthritis. Future Rheumatology, 2006, 1, 673-682.	0.2	1
132	Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 1270-1278.	6.7	37
133	The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 1283-1290.	6.7	25
134	Primary central nervous system vasculitis in children. Arthritis and Rheumatism, 2006, 54, 1291-1297.	6.7	202
135	Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies. Journal of Rheumatology, 2006, 33, 167-70.	1.0	40
136	Corticosteroid treatment of refractory Kawasaki disease. Journal of Rheumatology, 2006, 33, 803-9.	1.0	25
137	Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood, 2005, 106, 4152-4158.	0.6	106
138	Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 554-562.	6.7	69
139	Angiography-negative primary central nervous system vasculitis in children: A newly recognized inflammatory central nervous system disease. Arthritis and Rheumatism, 2005, 52, 2159-2167.	6.7	144
140	Effect of Maternal Autoantibodies on Fetal Cardiac Conduction: An Experimental Murine Model. Pediatric Research, 2005, 57, 557-562.	1.1	17
141	Leflunomide or Methotrexate for Juvenile Rheumatoid Arthritis. New England Journal of Medicine, 2005, 352, 1655-1666.	13.9	216
142	Infections and Kawasaki Disease: Implications for Coronary Artery Outcome. Pediatrics, 2005, 116, e760-e766.	1.0	127
143	Systemic Lupus Erythematosus. Pediatric Clinics of North America, 2005, 52, 443-467.	0.9	90
144	Radiographic vertebral morphology: A diagnostic tool in pediatric osteoporosis. Journal of Pediatrics, 2005, 146, 395-401.	0.9	80

#	Article	IF	CITATIONS
145	Longterm outcomes in patients with giant aneurysms secondary to Kawasaki disease. Journal of Rheumatology, 2005, 32, 928-34.	1.0	35
146	Nasal septal perforation: a novel clinical manifestation of systemic juvenile idiopathic arthritis/adult onset Still's disease. Journal of Rheumatology, 2005, 32, 2429-31.	1.0	24
147	Transplacental Fetal Treatment Improves the Outcome of Prenatally Diagnosed Complete Atrioventricular Block Without Structural Heart Disease. Circulation, 2004, 110, 1542-1548.	1.6	319
148	European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 49, 335-341.	6.7	52
149	Incidence and spectrum of neonatal lupus erythematosus: A prospective study of infants born to mothers with anti-Ro autoantibodies. Journal of Pediatrics, 2003, 142, 678-683.	0.9	233
150	Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. Journal of Pediatrics, 2003, 143, 666-669.	0.9	43
151	Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease. International Immunology, 2003, 15, 79-89.	1.8	75
152	Are Children With Kawasaki Disease and Prolonged Fever at Risk for Macrophage Activation Syndrome?. Pediatrics, 2003, 112, e495-e497.	1.0	52
153	Evaluation of eutectic lidocaine/prilocaine cream (EMLA) for steroid joint injection in children with juvenile rheumatoid arthritis: a double blind, randomized, placebo controlled trial. Journal of Rheumatology, 2003, 30, 594-6.	1.0	25
154	Maternal Anti-Ro and Anti-La Antibody–Associated Endocardial Fibroelastosis. Circulation, 2002, 105, 843-848.	1.6	202
155	Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. Journal of the American College of Cardiology, 2002, 40, 796-802.	1.2	163
156	Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. Journal of Pediatrics, 2002, 140, 450-455.	0.9	119
157	Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis and Rheumatism, 2002, 46, 436-444.	6.7	278
158	Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 1071-8.	1.0	20
159	Longterm followup of childhood lupus nephritis. Journal of Rheumatology, 2002, 29, 2635-42.	1.0	126
160	Cardiovascular risk factors after Kawasaki disease: A case-control study. Journal of Pediatrics, 2001, 138, 400-405.	0.9	76
161	Acute severe hepatitis with coagulopathy: An unusual presentation of Kawasaki syndrome in association with Epstein-Barr virus. Paediatrics and Child Health, 2001, 6, 627-630.	0.3	2
162	Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: A multicenter cohort study. Arthritis and Rheumatism, 2000, 43, 2402-2409.	6.7	124

#	Article	IF	CITATIONS
163	Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis. New England Journal of Medicine, 2000, 342, 763-769.	13.9	1,125
164	The health of mothers of children with cutaneous neonatal lupus erythematosus differs from that of mothers of children with congenital heart block. American Journal of Medicine, 2000, 108, 705-709.	0.6	37
165	Sensitivity of the systemic lupus erythematosus disease activity index, British Isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 1354-1360.	6.7	180
166	Diagnosis and management of stenotic aorto-arteriopathy in childhood. Journal of Pediatrics, 1998, 132, 1016-1022.	0.9	74
167	Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. Journal of Pediatrics, 1998, 132, 109-116.	0.9	69
168	The Relationship of Antiphospholipid Antibodies to Thromboembolic Events in Pediatric Patients with Systemic Lupus Erythematosus: A Cross-Sectional Study. Pediatric Research, 1998, 44, 351-356.	1.1	95
169	NEONATAL LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America, 1997, 23, 599-618.	0.8	49
170	Long-term outcome of mothers of children with complete congenital heart block. American Journal of Medicine, 1996, 100, 328-332.	0.6	105
171	Seasonal onset of systemic-onset juvenile rheumatoid arthritis. Journal of Pediatrics, 1996, 129, 513-518.	0.9	45
172	Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. Journal of Pediatrics, 1996, 128, 698-700.	0.9	45
173	Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis and Rheumatism, 1996, 39, 671-676.	6.7	73
174	Gastroesophageal Reflux and Esophagitis-Associated Hypertrophic Osteoarthropathy. Journal of Pediatric Gastroenterology and Nutrition, 1996, 23, 178-181.	0.9	12
175	Evaluation of the cytokine response in Kawasaki disease. Pediatric Infectious Disease Journal, 1995, 14, 199-202.	1.1	57
176	Prevalence of cardiac manifestations of juvenile ankylosing spondylitis. American Journal of Cardiology, 1995, 75, 744-746.	0.7	51
177	Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatric Neurology, 1995, 13, 191-197.	1.0	138
178	Cerebral vein thrombosis in childhood systemic lupus erythematosus. Journal of Pediatrics, 1995, 126, 722-727.	0.9	66
179	Localized scleroderma in childhood: A report of 30 cases. Seminars in Arthritis and Rheumatism, 1994, 23, 328-340.	1.6	92
180	Hypoprothrombinemia in childhood systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 1994, 24, 12-18.	1.6	60

#	Article	IF	CITATIONS
181	Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. Arthritis and Rheumatism, 1993, 36, 348-354.	6.7	123
182	Localized scleroderma progressing to systemic disease. case report and review of the literature. Arthritis and Rheumatism, 1993, 36, 410-415.	6.7	62
183	Limiting Dilution Analysis of Epstein-Barr Virus Infectable B Cells Secreting Anti-Ro/SSA and Anti-La/SSB Antibodies in Neonatal Lupus Erythematosus and Systemic Lupus Erythematosus. Journal of Autoimmunity, 1993, 6, 481-494.	3.0	11
184	Diagnostic use of B-cell alloantigen D8/17 in rheumatic chorea. Journal of Pediatrics, 1993, 123, 84-86.	0.9	35
185	Intrahepatic Cholestasis in Neonatal Lupus Erythematosus. Journal of Pediatric Gastroenterology and Nutrition, 1993, 17, 310-312.	0.9	29
186	MR Evaluation of the Temporomandibular Joint in Juvenile Rheumatoid Arthritis. Journal of Computer Assisted Tomography, 1993, 17, 449-454.	0.5	43
187	A Clinical Overview of Systemic Lupus Erythematosus in Childhood. Pediatrics in Review, 1993, 14, 194-201.	0.2	4
188	Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. Journal of Pediatrics, 1992, 120, 200-205.	0.9	69
189	High synovial immunoglobulin E levels in eosinophilic synovitis. Journal of Pediatrics, 1992, 121, 417-419.	0.9	7
190	Presence of thyroid abnormalities in children with systemic lupus erythematosus. Journal of Pediatrics, 1991, 119, 277-279.	0.9	38
191	Decreased protein binding of salicylates in Kawasaki disease. Journal of Pediatrics, 1991, 118, 456-459.	0.9	35
192	Treatment of dermatomyositis with intravenous gammaglobulin. American Journal of Medicine, 1991, 91, 169-172.	0.6	169
193	Primary pulmonary hypertension in a patient with systemicâ€onset juvenile arthritis. Arthritis and Rheumatism, 1991, 34, 1575-1579.	6.7	29
194	Abnormal t suppressor cell function in juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1990, 33, 205-211.	6.7	20
195	Pediatric onset of behcet's syndrome with myositis: case report and literature review illustrating unusual features. Arthritis and Rheumatism, 1990, 33, 418-425.	6.7	103
196	Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1990, 33, 1015-1022.	6.7	83
197	Liver disease in neonatal lupus erythematosus. Journal of Pediatrics, 1990, 116, 238-242.	0.9	112
198	Treatment of Kawasaki syndrome: A comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics, 1990, 117, 638-644.	0.9	69

#	Article	IF	CITATIONS
199	Serum-soluble interleukin-2 receptor levels in Kawasaki disease. Journal of Pediatrics, 1990, 116, 592-596.	0.9	40
200	Maternal antibodies to Ro (SS-A) are associated with both early onset of disease and male sex among children with systemic lupus erythematosus. Arthritis and Rheumatism, 1989, 32, 1414-1420.	6.7	25
201	Raynaud syndrome in childhood. Journal of Pediatrics, 1989, 114, 73-78.	0.9	60
202	Spontaneous tumor necrosis factor production in Kawasaki disease. Journal of Pediatrics, 1989, 115, 939-943.	0.9	77
203	Chronic recurrent multifocal osteomyelitis and psoriasis—A report of a new association and review of related disorders. Seminars in Arthritis and Rheumatism, 1988, 17, 260-270.	1.6	93
204	Determinants of low serum concentrations of salicylates in patients with Kawasaki disease. Journal of Pediatrics, 1988, 112, 663-667.	0.9	36
205	Beta-adrenergic receptors on human suppressor, helper, and cytolytic lymphocytes. Biochemical Pharmacology, 1986, 35, 1137-1142.	2.0	191
206	Different Patterns of C3 and C4 Activation in the Varied Types of Juvenile Arthritis. Pediatric Research, 1986, 20, 1332-1337.	1.1	8
207	Ultrastructural Features of Epidermolysis Bullosa. Ultrastructural Pathology, 1983, 5, 29-36.	0.4	23
208	Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. Journal of Pediatrics, 1983, 103, 872-876.	0.9	93
209	To Be or Not to Be: Surviving Immuneâ€Mediated Fetal Heart Disease. Journal of the American Heart Association, 0, , .	1.6	0